LANABIOTIC
Pre-Launchbacitracin; polymyxin b sulfate
NDATOPICALDISC
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LANABIOTIC is a topical antibiotic combination of bacitracin and polymyxin B sulfate in disc formulation, designed to prevent or treat bacterial infections at wound or surgical sites. This fixed-dose combination leverages two distinct mechanisms to provide broad-spectrum coverage against gram-positive and gram-negative bacteria. The product is currently in pre-launch stage, indicating it has not yet reached commercial availability.
Pre-Launch
Pre-launch stage offers opportunity to build brand positioning from inception, though team size and commercial scope remain to be determined post-approval.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LANABIOTIC at launch offers early career visibility in building a new brand in a crowded topical antibiotic space. Success will depend on differentiation strategy, payer coverage, and ability to compete against entrenched generics and branded alternatives.
Brand ManagerProduct Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.